Form 4: Tyra Biosciences Director Rehan Verjee Granted 22,200 Stock Options

Tyra Biosciences, Inc. Director Rehan Verjee was granted 22,200 stock options with an exercise price of $9.25, vesting monthly over one year.

Summary

• Rehan Verjee, a Director of Tyra Biosciences, Inc. (TYRA), was granted 22,200 stock options.
• The options have an exercise price of $9.25 per share.
• The grant date for these options was May 29, 2025.
• The options were granted under the Issuer's Non-Employee Director Compensation Program.
• Vesting occurs monthly, with 1/12th of the total shares vesting each month following the grant date.
• Any unvested portion will accelerate and vest on the date of the next annual stockholders' meeting if it occurs before the first anniversary of the grant date, contingent on continuous service.
• The options expire on May 28, 2035.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally a positive signal as it aligns management/director interests with shareholders. It's a standard compensation practice and doesn't indicate any immediate negative operational or financial issues.

Positives

• The granting of stock options to a director aligns their interests with shareholders, incentivizing long-term performance.
• The options are part of a standard Non-Employee Director Compensation Program, indicating a structured approach to executive incentives.

Risks

• The value of the options is dependent on the future stock price of Tyra Biosciences, Inc. exceeding the exercise price of $9.25.
• Vesting is subject to continuous service, meaning the director must remain with the company to fully realize the benefit.

Future Outlook

The granting of stock options to a director suggests a long-term commitment and incentivizes the director to contribute to the company's future growth and stock performance, aligning their interests with shareholders.

Management Comments

• The document is a Form 4, which reports a transaction and does not typically include direct management comments or quotes, other than the signature of the attorney-in-fact.

Industry Context

This transaction is a routine insider compensation event common across publicly traded companies, particularly in the biotechnology sector, where equity-based compensation is a standard practice to attract and retain talent and align interests with long-term company success.

Comparison to Industry Standards

• The granting of stock options to non-employee directors is a standard practice in the biotechnology and broader public company landscape.
• The vesting schedule (monthly over one year, with potential acceleration) is also typical for such grants, aiming to retain directors and incentivize sustained performance.
• Specific comparable companies or projects are not detailed in this transactional filing, but similar compensation structures are observed at companies like Moderna, BioNTech, or Gilead Sciences for their non-executive directors.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders by incentivizing stock price appreciation.

Next Steps

• The options will vest monthly over the next year, or potentially accelerate upon the next annual meeting of stockholders.
• The director may choose to exercise these options at any point before the expiration date of May 28, 2035, provided they are vested.

Key Dates

Keywords

Tyra Biosciences, TYRA, Form 4, SEC filing, stock options, insider transaction, director compensation, equity grant, beneficial ownership